HLA-B and cysteinylated ligands distinguish the antigen presentation landscape of extracellular vesicles

Extracellular vesicles can modulate diverse processes ranging from proliferation and tissue repair, to chemo-resistance and cellular differentiation. With the advent of tissue and immunological targeting, extracellular vesicles are also increasingly viewed as promising vectors to deliver peptide-based cancer antigens to the human immune system. Despite the clinical relevance and therapeutic potential of such 'cell-free' approaches, the natural antigen presentation landscape exported in extracellular vesicles is still largely uncharted, due to the challenging nature of such preparations and analyses. In the context of therapeutic vesicle production, a critical evaluation of the similarity in vesicular antigen presentation is also urgently needed. In this work, we compared the HLA-I peptide ligandomes of extracellular vesicles against that of whole-cells of the same cell line. We found that extracellular vesicles not only over-represent HLA-B complexes and peptide ligands, but also cysteinylated peptides that may modulate immune responses. Collectively, these findings describe the pre-existing provision of vesicular HLA complexes that may be utilized to carry peptide vaccines, as well as the propensity for different peptide and post-translationally modified ligands to be presented, and will outline critical considerations in devising novel EV vaccination strategies. Bauza-Martinez et al. analyzed the HLA-I peptide ligandome in extracellular vesicles (EVs) from an EBV-immortalized B cell line, JY, and compare HLA-I-binding peptides recovered from EVs to those recovered from whole-cells. The authors report an enrichment for HLA-B-binding peptides and for post-translationally modified cysteinylated peptides in EVs as compared to whole-cells.

Automated summary

Bauza-Martinez et al. analyzed the HLA-I peptide ligandome in extracellular vesicles (EVs) from an EBV-immortalized B cell line, JY, and compare HLA-I-binding peptides recovered from EVs to those recovered from whole-cells. The authors report an enrichment for HLA-B-binding peptides and for post-translationally modified cysteinylated peptides in EVs as compared to whole-cells.